Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
VISAGES Research Resource Report Resource Website 1+ mentions |
VISAGES Research (RRID:SCR_000749) | VisAGeS | data or information resource, organization portal, portal, topical portal | Research team focused on research and development of new algorithms in medical imaging, information processing and computer assisted intervention in the context of the pathologies of the central nervous system. Research team jointly affiliated to INSERM (National Institute of Health and Scientific Research), Inria (National Institute of Research in Computer Sciences and Automation) and IRISA / UMR CNRS 6074, University of Rennes I. Multidisciplinary team merging researchers in image processing and medical doctors. | team, image, processing, researcher, medical, doctor, development, algorithm, information, pathology, central, nervous, system |
is related to: Empenn has parent organization: University of Rennes 1; Rennes; France is parent organization of: Anima is parent organization of: Anima scripts |
Multiple Sclerosis, Epilepsy, Parkinson, Dementia, Stroke, Depression, Schizophrenia | nif-0000-10223 | https://www.irisa.fr/RA/D5/VISAGES/2015/visages2015.pdf | SCR_000749 | Vision Action and information manaGEment System in health, VisAGeS, VISAGES | 2026-09-03 04:43:54 | 5 | ||||||
|
MATRICS - Measurement And Treatment Research to Improve Cognition in Schizophrenia Resource Report Resource Website 1+ mentions |
MATRICS - Measurement And Treatment Research to Improve Cognition in Schizophrenia (RRID:SCR_005644) | MATRICS | knowledge environment | Cognitive deficits -- including impairments in areas such as memory, attention, and executive function -- are a major determinant and predictor of long-term disability in schizophrenia. Unfortunately, available antipsychotic medications are relatively ineffective in improving cognition. Scientific discoveries during the past decade suggest that there may be opportunities for developing medications that will be effective for improving cognition in schizophrenia. The NIMH has identified obstacles that are likely to interfere with the development of pharmacological agents for treating cognition in schizophrenia. These include: (1) a lack of a consensus as to how cognition in schizophrenia should be measured; (2) differing opinions as to the pharmacological approaches that are most promising; (3) challenges in clinical trial design; (4) concerns in the pharmaceutical industry regarding the US Food and Drug Administration''s (FDA) approaches to drug approval for this indication; and (5) issues in developing a research infrastructure that can carry out clinical trials of promising drugs. The MATRICS program will bring together representatives of academia, industry, and government in a consensus process for addressing all of these obstacles. Specific goals of the NIMH MATRICS are: * To catalyze regulatory acceptance of cognition in schizophrenia as a target for drug registration. * To promote development of novel compounds to enhance cognition in schizophrenia. * Leverage economic research power of industry to focus on important but neglected clinical targets. * Identify lead compounds and if deemed feasible, support human proof of concept trials for cognition in schizophrenia. | schizophrenia, cognitive deficit, memory, attention, executive function, disability, cognition, clinical | has parent organization: University of California at Los Angeles; California; USA | Schizophrenia | NIMH | nlx_146271 | SCR_005644 | Measurement And Treatment Research to Improve Cognition in Schizophrenia, Measurement Treatment Research to Improve Cognition in Schizophrenia | 2026-09-03 04:48:02 | 6 | ||||||
|
Human Imaging Database Resource Report Resource Website 1+ mentions |
Human Imaging Database (RRID:SCR_006126) | HID | data management software, data or information resource, data repository, database, image repository, service resource, software application, software resource, source code, storage service resource |
THIS RESOURCE IS NO LONGER IN SERVICE. Documented October 5, 2017. Database management system developed to handle the increasingly large and diverse datasets collected as part of the MBIRN and FBIRN collaboratories and throughout clinical imaging communities at large. The HID can be extended to contain relevant information concerning experimental subjects, assessments of subjects, the experimental data collected, the experimental protocols, and other metadata normally included with experiments. |
imaging, fmri, clinical, behavior, biomedical imaging data, mri |
is listed by: NeuroImaging Tools and Resources Collaboratory (NITRC) is related to: Cognitive Paradigm Ontology is related to: XCEDE Schema has parent organization: Biomedical Informatics Research Network |
Schizophrenia | PMID:19826494 PMID:18348946 |
THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-00269 | http://www.nitrc.org/projects/hid | http://fbirnbdr.nbirn.net:8080/BDR/ | SCR_006126 | fBIRN Data Repository, Human Imaging Database (HID) System, Function BIRN Data Repository | 2026-09-03 04:48:48 | 3 | |||
|
CNSforum: Image Bank Resource Report Resource Website |
CNSforum: Image Bank (RRID:SCR_002718) | data or information resource, image collection | A collection of downloadable central nervous system (CNS) images for teaching, presentations, articles, and other purposes. The following major categories of images are as follows: Brain anatomy, Brain physiology, Anxiety, Depression, Schizophrenia, Dementia, Parkinson's disease, Stroke, and Others. | image collection, human brain, brain anatomy, brain physiology, anxiety, depression, schizophrenia, dementia, parkinson's disease, stroke, brain | has parent organization: CNS Forum | Anxiety, Depressive Disorder, Schizophrenia, Dementia, Parkinson's disease, Stroke, Normal | Free, Freely available | nif-0000-23576 | SCR_002718 | CNS Forum Image Bank, Lundbeck Institute CNSforum Image Bank | 2026-09-03 04:45:37 | 0 | |||||||
|
Stanley Neuropathology Consortium Integrative Database Resource Report Resource Website 10+ mentions |
Stanley Neuropathology Consortium Integrative Database (RRID:SCR_002749) | SNCID | analysis service resource, data analysis service, data or information resource, data set, database, production service resource, service resource | A database of 1749 neuropathological markers measured in 12 different brain regions from 60 brains in the Consortium Collection from the Stanley Medical Research Institute combined with microarray data and statistical tools. Fifteen brains each are from patients diagnosed with schizophrenia, bipolar disorder, or major depression, and unaffected controls. The four groups are matched by age, sex, race, postmortem interval, pH, side of brain, and mRNA quality. A Repository of raw data is also included. Users must register for access. | schizophrenia, bipolar disorder, depressive disorder, brain, blinded study, microarray, single-nucleotide polymorphism, mental disorder, biomarker | has parent organization: Stanley Medical Research Institute | Schizophrenia, Bipolar Disorder, Depressive Disorder, Mental disorder | PMID:19829293 | Free | nif-0000-24103 | SCR_002749 | Stanley Neuropathology Consortium Integrative Database | 2026-09-03 04:45:39 | 20 | |||||
|
Brain Resource Company Resource Report Resource Website 10+ mentions |
Brain Resource Company (RRID:SCR_008019) | Brain Resource | standard specification, service resource, organization portal, database, material resource, portal, data or information resource, assessment test provider, training service resource, production service resource, narrative resource | Commercial provider of cognitive assessments, including their proprietary database, the Brain Resource International Database (BRID). The BRID is a database that allows users to quantify individual differences in brain function, compare individual performance against peers, and provide a robust frame of reference for clinical assessment and treatment decisions. The Brain Resource International Database provides evidence for the brain-behavior connection so important to reliably enabling optimal solutions for mental health and wellbeing. It powers all Brain Resource products. The database has collected over 50,000 datasets. There are over 4,000 healthy controls from the age of 6-100 in our normative database as well as large and growing clinical databases in Depression, Schizophrenia, Mild Cognitive Impairment, PTSD, ADHD and Brain Injury. Test standardization ensures total quality control and robust representative profiles in each disorder. | emotion, adhs, anxiety, behavior, brain, clinician, health, mild cognitive impairment, psychological, post-traumatic stress disorder, schizophrenia, cognition, brain training, healthy control, neuroplasticity, clinical, personalized medicine, adhd, brain assessment, biomarker, presenteeism, stress, assessment, neurocognition, questionnaire, FASEB list | Depressive Disorder, Attention deficit-hyperactivity disorder, Post-Traumatic Stress Disorder, Healthy control, Schizophrenia, Mild Cognitive Impairment, :Category:Traumatic Brain Injury | nif-0000-10179 | SCR_008019 | 2026-09-03 04:49:30 | 31 | |||||||||
|
Psychiatric Genomics Consortium Resource Report Resource Website 100+ mentions |
Psychiatric Genomics Consortium (RRID:SCR_004495) | PGC | analysis service resource, community building portal, computational hosting, consortium, data analysis service, data or information resource, data repository, organization portal, portal, production service resource, service resource, storage service resource | Consortium conducting meta-analyses of genome-wide genetic data for psychiatric disease. Focused on autism, attention-deficit hyperactivity disorder, bipolar disorder, major depressive disorder, schizophrenia, anorexia nervosa (AN), Tourette syndrome (TS), and obsessive-compulsive disorder (OCD). Used to investigate common single nucleotide polymorphisms (SNPs) genotyped on commercial arrays, structural variation (copy number variation) and uncommon or rare genetic variation. To participate you are asked to upload data from your study to central computer used by this consortium. Genetic Cluster Computer serves as data warehouse and analytical platform for this study . When data from your study have been incorporated, account will be provided on central server and access to all GWAS genotypes, phenotypes, and meta-analytic results relevant to deposited data and participation aims. NHGRI GWAS Catalog contains updated information about all GWAS in biomedicine, and is usually excellent starting point to find comprehensive list of studies. Files can be obtained by any PGC member for any disease to which they contributed data. These files can also be obtained by application to NIMH Genetics Repository. Individual-level genotype and phenotype data requires application, material transfer agreement, and informed consent consideration. Some datasets are also in controlled-access dbGaP and Wellcome Trust Case-Control Consortium repositories. PGC members can also receive back cleaned and imputed data and results for samples they contributed to PGC analyses. | structural variation, genetic variation, single nucleotide polymorphism, attention deficit-hyperactivity disorder, bipolar disorder, schizophrenia, mental disease, one mind ptsd, data sharing, visualization, genome-wide association study, genomic, genotype, phenotype, psychiatry, gwas, copy number variation, FASEB list |
is related to: Ricopili is related to: GWAS: Catalog of Published Genome-Wide Association Studies is related to: NCBI database of Genotypes and Phenotypes (dbGap) is related to: Wellcome Trust Case Control Consortium has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Mental disease, Attention deficit-hyperactivity disorder, Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Autism, Cross-disorder | Hersenstichting Nederland ; Netherlands Genetic Cluster Computer ; NIMH |
PMID:20955924 PMID:19895722 PMID:19648536 PMID:19339359 PMID:19002139 |
Restricted | nlx_143769 | https://pgc.unc.edu/ | SCR_004495 | Psychiatric Genomics Consortium, PGC, Psychiatric GWAS Consortium | 2026-09-03 04:47:15 | 121 | |||
|
University of Pittsburgh Brain Tissue Donation Program Resource Report Resource Website 1+ mentions |
University of Pittsburgh Brain Tissue Donation Program (RRID:SCR_005028) | UPMC Brain Tissue Donation Program, CCNMD Brain Tissue Donation Program | biomaterial supply resource, brain bank, material resource, tissue bank | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on March 19,2024. Brain tissue donation is a valuable contribution to mental health research. It enables scientists to investigate how the normal brain works, and how the brain is disturbed when it is affected by schizophrenia, depression, bipolar (manic depressive) disease or other related disorders. The Department of Psychiatry at the University of Pittsburgh has established a brain tissue bank to which brain tissue can be donated at no expense. The gift of brain tissue enables scientists to conduct research designed to understand causes, to develop new treatments, and ultimately to find cures for diseases that affect the brain. Brain tissue donation is a gift that makes it possible for researchers to study various types of mental disorders. Donations of brain tissue from individuals without these disorders are also needed to establish comparisons with brain samples from individuals who have these disorders. Any legally competent adult or guardian may indicate during life their interest in donating brain tissue after death. Next-of-kin either of healthy individuals or of those with psychiatric disorders may give consent to donate brain tissue following the death of a loved one. Brain tissue is removed during autopsy at a morgue or hospital and is transported to the University of Pittsburgh Medical Center for examination and study. | brain tissue, brain, tissue, mental disease, normal control, schizophrenia, depressive disorder, bipolar disorder, post mortem, early adult, middle adult |
is listed by: One Mind Biospecimen Bank Listing has parent organization: University of Pittsburgh Conte Center for the Neuroscience of Mental Disorders |
Mental disease, Normal control, Schizophrenia, Depressive Disorder, Bipolar Disorder | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_144013 | SCR_005028 | Conte Center Brain Tissue Donation Program, UPMC TNP Brain Tissue Donation Program, Conte Center for the Neuroscience of Mental Disorders Brain Tissue Donation Program, UPMC Center for the Neuroscience of Mental Disorders and Translational Neuroscience Program Brain Tissue Donation Program, University of Pittsburgh Medical Center Brain Tissue Donation Program | 2026-09-03 04:47:51 | 1 | ||||||
|
deCODE genetics Resource Report Resource Website 50+ mentions |
deCODE genetics (RRID:SCR_003334) | deCODE | commercial organization | A biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. They specialize in gene discovery - their population approach and resources have enabled them to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer. The company's genotyping capacity is now one of the highest in the world. They have a large population-based biobank containing whole blood and DNA samples with extensive relevant phenotypic information from around 120.000 Icelanders. In the company's work in more than 50 disease projects, their statistical and informatics departments have established themselves in data processing and analysis. deCODE genetics is widely recognized as a center of excellence in genetic research. | biopharmaceutical, genetics, drug, diagnostic, genotyping, phenotype, data processing, analysis, genetic variant, risk factor, genome, blood, dna, biobank, single nucleotide polymorphism |
is related to: EU-AIMS is related to: NEWMEDS |
Schizophrenia, Cardiovascular disease, Cancer, Type 2 diabetes, Atrial fibrillation, Heart attack | Free, Freely available | nif-0000-31959, ISNI: 0000 0004 0618 6889, grid.421812.c, Wikidata: Q493712 | https://ror.org/04dzdm737 | SCR_003334 | Islensk Erfdagreining EHF, Islensk Erfdagreining | 2026-09-03 04:46:16 | 67 | |||||
|
Harvard Brain Tissue Resource Center Resource Report Resource Website 10+ mentions |
Harvard Brain Tissue Resource Center (RRID:SCR_003316) | HBTRC | biomaterial supply resource, brain bank, material resource, tissue bank | Biomaterial supply resource that acquires, processes, stores, and distributes postmortem brain specimens for brain research. Various types of brain tissue are collected, including those with neurological and psychiatric disorders, along with their parents, siblings and offspring. The HBTRC maintains an extensive collection of postmortem human brains from individuals with Huntington's chorea, Alzheimer's disease, Parkinson's disease, and other neurological disorders. In addition, the HBTRC also has a collection of normal-control specimens. | biomaterial supply resource, brain tissue, brain, tissue, Huntington's disease, Parkinson's disease, mental disease, neurological disorder, Alzheimer's disease, schizophrenia, bipolar disorder, relative, parent, sibling, child, lewy body variant Alzheimer's disease, amyotrophic lateral sclerosis, dementia, unipolar depressive disorder, diffuse lewy body disease, dyt-1 dystonia, progressive supranuclear palsy, rett syndrome, Tourette's syndrome, restless legs syndrome, autism, post-mortem |
is listed by: One Mind Biospecimen Bank Listing is listed by: Multiple Sclerosis Discovery Forum is related to: One Mind Biospecimen Bank Listing is related to: Multiple Sclerosis Discovery Forum has parent organization: Harvard Medical School; Massachusetts; USA is parent organization of: National Brain Databank is parent organization of: Autism Tissue Program is parent organization of: RLS Foundation Brain Bank |
Huntington's disease, Parkinson's disease, Mental disease, Neurological disorder, Normal control, Alzheimers disease, Schizophrenia, Bipolar Disorder, Lewy Body Variant Alzheimer's disease, Amyotrophic Lateral Sclerosis, Dementia, Unipolar Depressive Dissorder, Diffuse Lewy Body Disease, DYT-1 Dystonia, Progressive Supranuclear Palsy, Rett Syndrome, Tourette's Syndrome | National Institutes of Health ; Private organizations ; NIH Blueprint for Neuroscience Research |
Free, Freely available | nif-0000-00192 | https://rarediseases.org/organizations/harvard-brain-tissue-resource-center/ | SCR_003316 | Harvard Brain Bank, The Brain Bank | 2026-09-03 04:46:11 | 25 | ||||
|
National Brain Databank Resource Report Resource Website |
National Brain Databank (RRID:SCR_003606) | National Brain Databank | data or information resource, data set, database | THIS RESOURCE IS NO LONGER IN SERVICE, documented September 6, 2016. A publicly accessible data repository to provide neuroscience investigators with secure access to cohort collections. The Databank collects and disseminates gene expression data from microarray experiments on brain tissue samples, along with diagnostic results from postmortem studies of neurological and psychiatric disorders. All of the data that is derived from studies of the HBTRC collection is being incorporated into the National Brain Databank. This data is available to the general public, although strict precautions are undertaken to maintain the confidentiality of the brain donors and their family members. The system is designed to incorporate MIAME and MAGE-ML based microarray data sharing standards. Data from various types of studies conducted on brain tissue in the HBTRC collection will be available from studies using different technologies, such as gene expression profiling, quantitative RT-PCR, situ hybridization, and immunocytochemistry and will have the potential for providing powerful insights into the subregional and cellular distribution of genes and/or proteins in different brain regions and eventually in specific subregions and cellular subtypes. | cellular, cortex, sequence data, molecular neuroanatomy resource, gene expression, microarray, brain tissue, post-mortem, neurological disorder, mental disease, human, gene expression profiling, quantitative rt pcr, in situ hybridization, immunocytochemistry, schizophrenia, bipolar disorder, huntington's disease, parkinson's disease | has parent organization: Harvard Brain Tissue Resource Center | Schizophrenia, Huntington's disease, Parkinson's disease, bipolar disorder | NIMH ; NINDS |
THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-00071 | SCR_003606 | National Brain Databank: Brain Tissue Gene Expression Repository | 2026-09-03 04:46:37 | 0 | |||||
|
Psynova Neurotech Resource Report Resource Website 1+ mentions |
Psynova Neurotech (RRID:SCR_003959) | Psynova | commercial organization | Commercial organization focused on the development and exploitation of novel biomarkers for psychiatric illnesses. They provide industrial and academic partners with comprehensive biomarker discovery services in commercial and collaborative projects. They operate in the field of psychiatric disorders and their products and services are designed to excel biomarker research. In 2010, Psynova Neurotech and its partner company Rules-Based-Medicine Inc (now MyriadRBM) conducted a beta launch of a blood test aiding in the diagnosis of schizophrenia (http://www.veripsych.com/). They are now refining the test and have shifted their focus to the development of new blood-based biomarker tests that aid in the diagnosis, prognosis and differential diagnosis of schizophrenia, bipolar disorder and major depression. They offer not only their pre-selceted Multiple Reaction Monitoring (MRM) and Multiplex Immunoassay products, but also custom build panels. If they are provided with a list of analyses to evaluate, they can produce an analytical panel according to individual needs utilizing either MRM or Multiplex Immunoassay technologies., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biomarker, neuropsychiatry, preclinical, model, diagnosis, blood, drug response, immunoassay, brain tissue, mass spectrometry, analysis |
is related to: University of Cambridge; Cambridge; United Kingdom is related to: NEWMEDS |
Schizophrenia, Psychiatric disorder, Bipolar Disorder, Major Depressive Disorder | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158360 | SCR_003959 | Psynova Neurotech Ltd | 2026-09-03 04:46:48 | 9 | ||||||
|
CATIE - Clinical Antipsychotic Trials in Intervention Effectiveness Resource Report Resource Website |
CATIE - Clinical Antipsychotic Trials in Intervention Effectiveness (RRID:SCR_005615) | CATIE, CATIE Schizophrenia, Clinical Antipsychotic Trials in Intervention Effectiveness | clinical trial | The NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study was a nationwide public health-focused clinical trial that compared the effectiveness of older (first available in the 1950s) and newer (available since the 1990s) antipsychotic medications used to treat schizophrenia. These newer medications, known as atypical antipsychotics, cost roughly 10 times as much as the older medications. CATIE is the largest, longest, and most comprehensive independent trial ever done to examine existing therapies for this disease. Schizophrenia is a brain disorder characterized by hallucinations, delusions, and disordered thinking. The course of schizophrenia is variable, but usually is recurrent and chronic, often causing severe disability. Previous studies have shown that taking antipsychotic medications consistently is far more effective than taking no medicine and that the drugs are necessary to manage the disease. The aim of the CATIE study was to determine which medications provide the best treatment for schizophrenia. Additional information may be found by following the links, http://www.nimh.nih.gov/trials/practical/catie/index.shtml, http://www.clinicaltrials.gov/ct/show/NCT00014001?order=1 | schizophrenia, clinical trial, treatment, outcome, antipsychotic |
is used by: Limited Access Datasets From NIMH Clinical Trials is listed by: ClinicalTrials.gov is related to: CATIE - Alzheimers Disease is related to: NIMH Repository and Genomics Resources has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Schizophrenia | NIMH | SCR_005512, nlx_146233, nlx_146234 | http://www.nimh.nih.gov/health/trials/practical/catie/phase1results.shtml | http://www.nimh.nih.gov/health/trials/practical/catie/index.shtml | SCR_005615 | CATIE Schizophrenia Study, Clinical Antipsychotic Trials in Intervention Effectiveness, Clinical Antipsychotic Trials in Intervention Effectiveness - Schizophrenia | 2026-09-03 05:04:13 | 0 | ||||
|
PolygenicBlog Resource Report Resource Website |
PolygenicBlog (RRID:SCR_008789) | blog, data or information resource, narrative resource | A blog concerning the relationships between genes, risk factors and immunity in Alzheimer's disease, autism, Bipolar disorder, multiple sclerosis, Parkinson's disease, schizophrenia and chronic fatigue. | gene, risk factor, immunity, alzheimer's disease, autism, bipolar disorder, multiple sclerosis, parkinson's disease, schizophrenia, chronic fatigue |
is used by: NIF Data Federation is used by: Integrated Blogs has parent organization: Polygenic Pathways |
Alzheimer's disease, Autism, Bipolar disorder, Multiple sclerosis, Parkinson's disease, Schizophrenia, Chronic fatigue | Public | nlx_144238 | SCR_008789 | Polygenic Blog | 2026-09-03 05:02:52 | 0 | |||||||
|
Brain-Net Resource Report Resource Website 10+ mentions |
Brain-Net (RRID:SCR_005017) | biomaterial supply resource, material resource, tissue bank | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 28,2022. A network of several university centers in Germany that classifies neurological and psychiatric disorders neuropathologically and collects and provides brain tissue for research. The aim and task of the Brain-Net are: the collection of clinically and neuropathologically well-characterized brain tissue samples; the standardization of neuropathological diagnoses according to internationally accepted criteria; and providing a basis for future research projects using genetic, epidemiological, biometric and other issues to neurological and psychiatric disorders. | brain, tissue, autopsy, neurological disorder, mental disease, parkinson's disease, dementia, schizophrenia, suicidal tendency, depressive disorder, suicide, alzheimer's disease, amyotrophic lateral sclerosis, post mortem |
is listed by: One Mind Biospecimen Bank Listing has parent organization: Ludwig-Maximilians-University; Munich; Germany |
Neurological disorder, Mental disease, Parkinson's disease, Dementia, Schizophrenia, Suicidal tendency, Depressive disorder, Alzheimer's disease, Amyotrophic lateral sclerosis | German Federal Ministry of Research and Education | THIS RESOURCE IS NO LONGER IN SERVICE. | nlx_144007 | SCR_005017 | BrainNet Germany, BrainNet | 2026-09-03 05:01:49 | 13 | ||||||
|
National Disease Research Interchange Resource Report Resource Website 100+ mentions Rating or validation data |
National Disease Research Interchange (RRID:SCR_000550) | NDRI | biomaterial supply resource, material resource, tissue bank | NDRI is a Not-For-Profit (501c3) Corporation dedicated to providing the highest quality human biomaterials for research. NDRI makes it easy for researchers to get the human tissues and organs they need, prepared, preserved and shipped precisely according to their specific scientific protocols, as quickly as possible, and in the largest available quantities. NDRI provides researchers with protocol specific human neurological tissues such as brain stem, spinal cord, and basal ganglia, among others. In addition to control specimens, NDRI recovers tissues from donors with a variety of diseases, including Down syndrome, Parkinsons disease, Alzheimers disease, schizophrenia, and dementia. Through the NDRI 24/7 referral and procurement system, research consented biospecimens can be provided from low post mortem interval donors preserved at 4ºC, frozen or snap frozen, fixed, paraffin embedded, or as unstained slides. | neurological, tissue, organ, cell, neurological tissue, brainstem, spinal cord, basal ganglia, cerebral cortex, hippocampus, frozen, snap frozen, fixed, paraffin embedded, unstained slide, disease, down syndrome, parkinson's disease, alzheimer's disease, schizophrenia, dementia, control, normal, catalog |
is listed by: One Mind Biospecimen Bank Listing is listed by: Multiple Sclerosis Discovery Forum is listed by: Biospecimens/Biorepositories: Rare Disease-HUB (RD-HUB) is parent organization of: Human Tissue and Organ for Research Resource (HTORR) is parent organization of: Human Biological Data Interchange is parent organization of: NDRI Dorsal Root Ganglia Program |
Down syndrome, Parkinson's disease, Alzheimer's disease, Schizophrenia, Dementia | NIH OD011158 | Public: NDRI is a nonprofit organization that procures and distributes normal and diseased human biomaterials to biomedical researchers in academia, government, and industry. | nlx_99804 | SCR_000550 | 2026-09-03 05:00:43 | 192 | ||||||
|
Internet Brain Volume Database Resource Report Resource Website 1+ mentions |
Internet Brain Volume Database (RRID:SCR_002060) | IBVD | data or information resource, database | A database of brain neuroanatomic volumetric observations spanning various species, diagnoses, and structures for both individual and group results. A major thrust effort is to enable electronic access to the results that exist in the published literature. Currently, there is quite limited electronic or searchable methods for the data observations that are contained in publications. This effort will facilitate the dissemination of volumetric observations by making a more complete corpus of volumetric observations findable to the neuroscience researcher. This also enhances the ability to perform comparative and integrative studies, as well as metaanalysis. Extensions that permit pre-published, non-published and other representation are planned, again to facilitate comparative analyses. Design strategy: The principle organizing data structure is the "publication". Publications report on "groups" of subjects. These groups have "demographic" information as well as "volume" information for the group as a whole. Groups are comprised of "individuals", which also have demographic and volume information for each of the individuals. The finest-grained data structure is the "individual volume record" which contains a volume observation, the units for the observation, and a pointer to the demographic record for individual upon which the observation is derived. A collection of individual volumes can be grouped into a "group volume" observation; the group can be demographically characterized by the distribution of individual demographic observations for the members of the group. | anatomy, volume, dsm-iv, normal, schizophrenia, autistic disorder, bipolar disorder, major depressive disorder, alzheimer's disease, attention deficit-hyperactivity disorder, alcohol dependence, dementia, traumatic brain injury, borderline personality disorder, obsessive-compulsive disorder, asperger syndrome, brain, brain structure, in vivo, ex vivo, male, female, gorilla beringei beringei, pongo pygmaeus, volumetric analysis |
is listed by: NeuroImaging Tools and Resources Collaboratory (NITRC) is related to: NIF Data Federation is related to: Integrated Manually Extracted Annotation has parent organization: Harvard Medical School; Massachusetts; USA |
Normal, Alzheimers disease, Seizure, Complex febrile seizure, Holoprosencephaly, Alcohol dependence, Bipolar Disorder, Traumatic brain injury, Schizophrenia | The Human Brain Project ; NINDS NS034189 |
PMID:21931990 | Free, Available for download, Freely available | nif-0000-00033 | http://www.nitrc.org/projects/ibvd | http://www.cma.mgh.harvard.edu/ibvd/ | SCR_002060 | 2026-09-03 05:00:46 | 4 | |||
|
Alkermes Resource Report Resource Website |
Alkermes (RRID:SCR_010497) | ALKS | commercial organization | A biopharmaceutical company that focuses on central nervous system (CNS) diseases. The company is the result of a merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Elan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases such as addiction, schizophrenia, diabetes and depression. Among these, five products are primary to the company: risperidone Long-Acting Injection (Risperdal Consta) for schizophrenia and bipolar 1 disorder, paliperidone palmitate (Invega Sustenna in the U.S., Xeplion in Europe) for schizophrenia, 4-aminopyridine (Ampyra in the U.S., Fampyra in Europe) to improve walking in patients with multiple sclerosis, naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence, and exenatide extended-release for injectable suspension (Bydureon) for the treatment of type 2 diabetes. Bydureon is a once-weekly, long-acting form of the drug exenatide (Byetta) and was developed through a partnership between Amylin, Alkermes and Eli Lilly. It is approved in Europe and the U.S. (Wikipedia) | central nervous system, disease, biopharmaceutical company, drug | Central nervous system disease, Addiction, Schizophrenia, Diabetes, Depressive Disorder, Bipolar Disorder, Multiple Sclerosis, Alcohol dependence, Opioid dependence, Type 1 diabetes, Type 2 diabetes | ISNI: 0000 0004 0384 2510, nlx_158068, Wikidata: Q4727688, grid.472773.2 | https://ror.org/05sa44m96 | SCR_010497 | Alkermes plc | 2026-09-03 04:50:17 | 0 | |||||||
|
NIMH Repository and Genomics Resources Resource Report Resource Website 50+ mentions |
NIMH Repository and Genomics Resources (RRID:SCR_006698) | NRGR, RGR | institution | Collaborative venture between the National Institute of Mental Health (NIMH) and several academic institutions. Repository facilitates psychiatric genetic research by providing patient and control samples and phenotypic data for wide-range of mental disorders and Stem Cells.Stores biosamples, genetic, pedigree and clinical data collected in designated NIMH-funded human subject studies. RGR database likewise links to other repositories holding data from same subjects, including dbGAP, GEO and NDAR. Allows to access these data and biospecimens (e.g., lymphoblastoid cell lines, induced pluripotent cell lines, fibroblasts) and further expand genetic and molecular characterization of patient populations with severe mental illness. | biosamples, genetic, pedigree, clinical, data |
is listed by: One Mind Biospecimen Bank Listing is related to: NIMH Stem Cell Center is related to: Rutgers Cell and DNA Repository is related to: Sequenced Treatment Alternatives to Relieve Depression Study is related to: CATIE - Clinical Antipsychotic Trials in Intervention Effectiveness is related to: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) is related to: NKI-RS Enhanced Sample has parent organization: Rutgers University; New Jersey; USA has parent organization: Washington University in St. Louis; Missouri; USA has parent organization: University of Southern California; Los Angeles; USA |
Bipolar Disorder, Schizophrenia, Alzheimer's disease, Autism, Attention deficit-hyperactivity disorder, Depression, Control, Obsessive-Compulsive Disorder, Anorexia Nervosa, Relative, Mental disorder, Brain disorder, Relative | National Institute for Mental Health ; NIH Blueprint for Neuroscience Research |
Restricted | grid.482687.7, nif-0000-00186, SCR_016318 | https://ror.org/026dax180 | SCR_006698 | NIMH: Center for Collaborative Genetic Studies, NIMH Human Genetics Initiative, NIMH Center for Genetic Studies, NIMH Genetics, Center for Collaborative Genomic Studies on Mental Disorders, NIMH Repository and Genomics Resources (NRGR) | 2026-09-03 04:48:43 | 66 | ||||
|
Wellcome Trust Case Control Consortium Resource Report Resource Website 100+ mentions |
Wellcome Trust Case Control Consortium (RRID:SCR_001973) | WTCCC | data or information resource | Consortium of 50 research groups across the UK to harness the power of newly-available genotyping technologies to improve our understanding of the aetiological basis of several major causes of global disease. The consortium has gathered genotype data for up to 500,000 sites of genome sequence variation (single nucleotide polymorphisms or SNPs) in samples ascertained for the disease phenotypes. Analysis of the genome-wide association data generated has lead to the identification of many SNPs and genes showing evidence of association with disease susceptibility, some of which will be followed up in future studies. In addition, the Consortium has gained important insights into the technical, analytical, methodological and biological aspects of genome-wide association analysis. The core of the study comprised an analysis of 2,000 samples from each of seven diseases (type 1 diabetes, type 2 diabetes, coronary heart disease, hypertension, bipolar disorder, rheumatoid arthritis and Crohn's disease). For each disease, the case samples have been ascertained from sites widely distributed across Great Britain, allowing us to obtain considerable efficiencies by comparing each of these case populations to a common set of 3,000 nationally-ascertained controls also from England, Scotland and Wales. These controls come from two sources: 1,500 are representative samples from the 1958 British Birth Cohort and 1,500 are blood donors recruited by the three national UK Blood Services. One of the questions that the WTCCC study has addressed relates to the relative merits of these alternative strategies for the generation of representative population cohorts. Genotyping for this main Case Control study was conducted by Affymetrix using the (commercial) Affymetrix 500K chip. As part of this study a total of 17,000 samples were typed for 500,000 SNPs. There are two additional components to the study. First, the WTCCC award is part-funding a study of host resistance to infectious diseases in African populations. The same approach has been used to type 2,000 cases of tuberculosis (TB) and 2,000 cases of malaria, as well as 2,000 shared controls. As well as addressing diseases of major global significance, and extending WTCCC coverage into the area of infectious disease, the inclusion of samples of African origin has obvious benefits with respect to methodological aspects of genome-wide association analysis. Second, the WTCCC has, for four additional diseases (autoimmune thyroid disease, breast cancer, ankylosing spondylitis, multiple sclerosis), completed an analysis of 15,000 SNPs designed to represent a large proportion of the known non-synonymous coding SNPs across the genome. This analysis has been performed at the WTSI using a custom Infinium chip (Illumina). Data release The genotypic data of the control samples (1958 British Birth Cohort and UK Blood Service) and from seven diseases analyzed in the main study are now available to qualified researchers. Summary genotype statistics for these collections are available directly from the website. Access to the individual-level genotype data and summary genotype statistics is by application to the Consortium Data Access Committee (CDAC) and approval subject to a Data Access Agreement. WTCCC2: A further round of GWA studies were funded in April 2008. These include 15 WTCCC-collaborative studies and 12 independent studies be supported totaling approximately 120,000 samples. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC2 will perform genome-wide association studies in 13 disease conditions: Ankylosing spondylitis, Barrett's oesophagus and oesophageal adenocarcinoma, glaucoma, ischaemic stroke, multiple sclerosis, pre-eclampsia, Parkinson's disease, psychosis endophenotypes, psoriasis, schizophrenia, ulcerative colitis and visceral leishmaniasis. WTCCC2 will also investigate the genetics of reading and mathematics abilities in children and the pharmacogenomics of statin response. Over 60,000 samples will be analyzed using either the Affymetrix v6.0 chip or the Illumina 660K chip. The WTCCC2 will also genotype 3,000 controls each from the 1958 British Birth cohort and the UK Blood Service control group, and the 6,000 controls will be genotyped on both the Affymetrix v6.0 and Illumina 1.2M chips. WTCCC3: The Wellcome Trust has provided support for a further round of GWA studies in January 2009. These include 5 WTCCC-collaborative studies to be carried out in WTCCC3 and 5 independent studies, across a range of diseases. Many of the studies represent major international collaborative networks that have together assembled large sample collections. WTCCC3 will perform genome-wide association studies in the following 4 disease conditions: primary biliary cirrhosis, anorexia nervosa, pre-eclampsia in UK subjects, and the interactions between donor and recipient DNA related to early and late renal transplant dysfunction. The WTCCC3 will also carry out a pilot in a study of the genetics of host control of HIV-1 infection. Over 40,000 samples will be analyzed using the Illumina 660K chip. The WTCCC3 will utilize the 6,000 control genotypes generated by the WTCCC2. | gene, genomic, genetics, microarray, genome-wide association study, snp, genome-wide association, blood, dna, genotype, variation, genome, sequence variant, copy number variation, genetic variation, phenotype, disease |
is related to: Psychiatric Genomics Consortium has parent organization: Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
Bipolar disorder, Coronary artery disease, Crohn's disease, Rheumatoid arthritis, Type 1 diabetes, Type 2 diabetes, Hypertension, Control, Multiple sclerosis, Breast cancer, Ankylosing spondylitis, Autoimmune thyroid disease, Malaria, Tuberculosis, Inflammatory bowel disease, Barrett's esophagus, Esophageal adenocarcinoma, Glaucoma, Ischemic stroke, Pre-eclampsia, Parkinson's disease, Psychosis endophenotypes, Psoriasis, Schizophrenia, Ulcerative colitis, Visceral leishmaniasis, Primary biliary cirrhosis, Anorexia nervosa, Human immunodeficiency virus, Renal transplant dysfunction, Diabetes | Wellcome Trust ; Bill and Melinda Gates Foundation ; Wellcome Trust Sanger Institute; Hinxton; United Kingdom |
PMID:17554300 | Access to summary data and individual-level genotype data is available by application to the Wellcome Trust Case Control Consortium Data Access Committee. Access to data will be granted to qualified investigators for appropriate use. | nif-0000-10551 | SCR_001973 | Wellcome Trust Case-Control Consortium (WTCCC) | 2026-09-03 04:45:07 | 221 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the kravitz2 Resources search. From here you can search through a compilation of resources used by kravitz2 and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that kravitz2 has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on kravitz2 then you can log in from here to get additional features in kravitz2 such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into kravitz2 you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Data set from Kravitz, Owen and Kretizer's 2012 paper "Optogenetic identification of striatal projection neuron subtypes during in vivo recordings."
